Tech Company Financing Transactions
Satsuma Pharmaceuticals Funding Round
Wellington Management Company, CAM Capital and Cormorant Asset Management participated in a $62 million Series B funding round for Satsuma Pharmaceuticals. This VC investment round was announced on 4/26/2019.
Transaction Overview
Company Name
Announced On
4/26/2019
Transaction Type
Venture Equity
Amount
$62,000,000
Round
Series B
Investors
Proceeds Purpose
Funding supports Phase 3 development of STS101 for the acute treatment of migraine
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
400 Oyster Point Blvd. 221
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Satsuma Pharmaceuticals (Nasdaq: STSA) is focused on developing best-in-class products to address the unmet needs of migraine sufferers.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
John Kollins
Chief Financial Officer
Thomas O'Neil
Chief Medical Officer
Detlef Albrecht
Vice President
Robert Schultz
VP - Operations
Mic Iwashima
VP - Regulatory Affairs
Shannon Strom
Browse more venture capital transactions:
Prev: 4/26/2019: Labster venture capital transaction
Next: 4/26/2019: Tempo Automation venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs